TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05307666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication minimization
Description: During the medication minimization visit, and any necessary follow-up visits, patients and providers work together to gradually minimize medication dosages (e.g. reducing 1/4 or 1/2 dose at a time) using the following approach: 1) Medications Treating Symptoms: Find the minimum dose that controls the symptom, 2) Drugs that Lower Blood Pressure: Reduce dosages until systolic BP is in the upper 10mmHg of the target range (e.g. target 130 - 140 mmHg), 3) Drugs That Lower Blood Sugar: Reduce dosages until HbA1c is in the upper 5% of the target range (e.g. target 7.5 - 8.0%).
Study: NCT06461637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care Mental Health for Foreign Domestic Helpers (SCMH-FDH)
Description: The SCMH-FDH intervention consists of 4 steps. Step 1 involves a self-help intervention (through 12 mental health booklets) delivered in 6 sessions and an online peer support group. Those who did not respond to Step 1 will be referred to Step 2 (group-based resilience workshop). The intervention will be also be delivered in 6 weekly sessions lasting 1-1.5-hours. Those who did not respond to Step 2 will be referred to Step 3 (guided self-help cognitive behavioral therapy, CBT) with guidance from a trained therapist. Self-help materials will be provided. The sessions are spread out over six weeks, with each sessions lasting 30-45 minutes. Those who did not respond to Step 3 will be referred to Step 4 (high intensity interventions provided by mental health professionals). Stepping up is determined by the IAPT-minimum data set. If assessment scores after previous treatment exceeds the defined threshold (PHQ-9 ≥ 10 or GAD-7 ≥ 8), then participants need to step up to the next intervention.
Study: NCT06072872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of portable CPAP
Description: Patients use portable CPAP during exercise
Study: NCT04812171

Intervention type: PROCEDURE
Intervention: non-surgical endodontic treatment
Description: standard non-surgical endodontic treatment performed by endodontic specialist

Intervention type: PROCEDURE
Intervention: non-surgical endodontic treatment
Description: standard non-surgical endodontic treatment performed by endodontic specialist
Study: NCT05186883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic parathyroid cells
Description: Allogenic parathyroid cells

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment of postoperative hypoparathyroidism according to the Clinical protocols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment of postoperative hypoparathyroidism according to the Clinical protocols
Study: NCT04124029

Intervention type: PROCEDURE
Intervention: No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.
Description: No intervention will be used.

Intervention type: PROCEDURE
Intervention: No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.
Description: No intervention will be used.

Intervention type: PROCEDURE
Intervention: No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.
Description: No intervention will be used.

Intervention type: PROCEDURE
Intervention: No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.
Description: No intervention will be used.

Intervention type: PROCEDURE
Intervention: No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.
Description: No intervention will be used.

Intervention type: PROCEDURE
Intervention: No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.
Description: No intervention will be used.
Study: NCT04300023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cycling Group
Description: engaged with a research staff member for 30 minutes of cycling
Study: NCT05227066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adding lower extremity weights
Description: All children in the two groups received physical therapy protocol for 30 minutes in addition to half kg of sandbags weights attached for each leg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy group
Description: traditional physical therapy group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy group
Description: traditional physical therapy group
Study: NCT05380921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard EEG
Description: all subjects will receive both a standard EEG and a dry electrode EEG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dry electrode EEG
Description: all subjects will receive both a standard EEG and a dry electrode EEG
Study: NCT05524311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Oral tablets (2 mg) will be used For children \> or = 6 years: 4 mg once a day (2 x 2 mg) during the 24 weeks-period study For children \< 6 years: 2 mg once a day during the 24 weeks -period study
Study: NCT06468982

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intra-aortic Balloon Pump
Description: in patients with acute myocardial infarction involving elevated troponin levels and recurrent or persistent chest pain at rest, hemodynamic instability, multivessel disease, left main coronary artery disease, and narrow and/or tortuous coronary artery anatomy in which PCI has failed or is not feasible.
Study: NCT06661746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal IV analgesia
Description: Multimodal IV analgesia of lidocaine, ketamine and MS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural analgesia
Description: Opioid-based and epidural analgesia
Study: NCT06158048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: An initial infusion dose of prophylactic phenylephrine (0.5 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.1 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT06747819

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cervical Epidural Steroid Injection (CESI)
Description: Participants in this group received CESI to reduce inflammation and alleviate pain in the cervical nerve roots.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Neural Mobilization (NM)
Description: Participants in this group underwent NM exercises aimed at improving nerve mobility and reducing symptoms related to nerve compression.
Study: NCT05212571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-ketamine infusion inpatient setting
Description: S-ketamine is administered intravenously for six consecutive days. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine infusion outpatient setting
Description: S-ketamine is administered intravenously for six hours. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.
Study: NCT05876130

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: POHIM_EM
Description: hypofractionated intensity-modulated radiation therapy (2.5 Gy/fraction, 16 fractions)
Study: NCT03615248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreatheSuite
Description: BreatheSuite (patent pending) is a device and mobile application developed by Mr. Brett Vokey, an engineering student at Memorial University of Newfoundland. BreatheSuite has been recognized by numerous provincial competitions, featured at the Eastern Health Innovation Showcase, and was recently selected as a finalist for the New York Health Innovation Challenge.~This device attaches to metered dose inhalers and it can determine if:~1. the dose was given,~2. the metered dose inhaler was properly shaken,~3. the metered dose inhaler is properly aligned,~4. the flow of medication is appropriate and~5. there is no accidental exhalation into the inhaler.
Study: NCT05964231

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Heat-treated PS23
Description: Lactobacillus paracasei PS23 heat-treated, 2caps daily use

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose, 2caps daily use
Study: NCT06409078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated transcranial magnetic stimulation treatment group
Description: Patients with irritable bowel syndrome received repetitive transcranial magnetic stimulation at 1 Hz/s for 20 minutes for 1 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Western medicine group
Description: Patients with irritable bowel syndrome were given pivotal ammonium bromide tablets orally at 50 mg three times daily for seven days in the Western medicine group.
Study: NCT05142332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Covid-19 vaccine education materials
Description: videos and flyers containing Covid-19 vaccine educational information
Study: NCT05200247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spesolimab
Description: solution for infusion
Study: NCT06242899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise with a cycle ergometer in three phases:~* Warm-up: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes.~* Short exercise at moderate intensity for 8, 10 or 15 minutes according to group allocation. The exercise was cycling at 75% HRmax determined with an effort test.~* Cool down: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise with a cycle ergometer in three phases:~* Warm-up: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes.~* Short exercise at moderate intensity for 8, 10 or 15 minutes according to group allocation. The exercise was cycling at 75% HRmax determined with an effort test.~* Cool down: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise with a cycle ergometer in three phases:~* Warm-up: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes.~* Short exercise at moderate intensity for 8, 10 or 15 minutes according to group allocation. The exercise was cycling at 75% HRmax determined with an effort test.~* Cool down: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes.
Study: NCT05524311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pharmacokinetics study
Description: additionnal blood sampling at week 4, 8, 12, and 24

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dosage of cytokines
Description: additionnal blood sampling at weeks 0, 4 and 24

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: transcriptomic analysis
Description: additionnal blood sampling at weeks 0, 4 and 24

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent version of the Child Health Questionnaire (CHQ)
Description: Evaluate by parents at each visits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Childhood Health Assessment Questionnaire
Description: Evaluate by parents at each visits

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pregnancy test
Description: Urine pregnancy test at V4 A dosage of bHCG with current biological analysis is done at each visit (except V4)
Study: NCT05528861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirentelimab (AK002)
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04983888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1g IV on day one and 1 g IV on day 15, followed by identical course at month 6
Study: NCT05373342

Intervention type: DEVICE
Intervention: iCount system assembled with swabs
Description: Designed as single use. Intended purpose - To be used to count swabs and tampons after childbirth in an objective manner. This is intended to be used in women during and after childbirth.
Study: NCT06582056

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Investigational Procedure
Description: It consists of prospective blood and/or tissue collection from healthy subjects and/or patients with the appropriate clinical annotation. Study without any IMP administration.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Investigational Procedure
Description: It consists of prospective blood and/or tissue collection from healthy subjects and/or patients with the appropriate clinical annotation. Study without any IMP administration.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Investigational Procedure
Description: It consists of prospective blood and/or tissue collection from healthy subjects and/or patients with the appropriate clinical annotation. Study without any IMP administration.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Investigational Procedure
Description: It consists of prospective blood and/or tissue collection from healthy subjects and/or patients with the appropriate clinical annotation. Study without any IMP administration.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Investigational Procedure
Description: It consists of prospective blood and/or tissue collection from healthy subjects and/or patients with the appropriate clinical annotation. Study without any IMP administration.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Investigational Procedure
Description: It consists of prospective blood and/or tissue collection from healthy subjects and/or patients with the appropriate clinical annotation. Study without any IMP administration.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Investigational Procedure
Description: It consists of prospective blood and/or tissue collection from healthy subjects and/or patients with the appropriate clinical annotation. Study without any IMP administration.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Investigational Procedure
Description: It consists of prospective blood and/or tissue collection from healthy subjects and/or patients with the appropriate clinical annotation. Study without any IMP administration.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Investigational Procedure
Description: It consists of prospective blood and/or tissue collection from healthy subjects and/or patients with the appropriate clinical annotation. Study without any IMP administration.
Study: NCT05443828

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast Control Meal
Description: The participants consumed extruded puff with added vitacel (cellulose) as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast Test Meal
Description: The participants consumed bread with added arabynoxylans (AX) as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast Test Meal
Description: The participants consumed extruded puff with added wheat bran as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
Study: NCT06386419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inclisiran
Description: Inclisiran sodium 300 mg SC. Three single doses of inclisiran sodium will be administered to the participants on Day 1, Day 90, and Day 270, respectively
Study: NCT06237868

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS Active
Description: The participants undergo Active rTMS, approximately 10-15 min and then complete tasks and questionnaires.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS Sham
Description: The participants undergo Sham rTMS, approximately 10-15 min and then complete tasks and questionnaires.
Study: NCT05657847

Intervention type: DEVICE
Intervention: Photon-counting detector-CT
Description: CT scan

Intervention type: DEVICE
Intervention: Photon-counting detector-CT
Description: CT scan

Intervention type: DEVICE
Intervention: Photon-counting detector-CT
Description: CT scan
Study: NCT06388629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rook Epicardial Access Kit
Description: Access the epicardial surface of the heart via a subxiphoid approach with the subject device to facilitate guidewire placement into the pericardium.
Study: NCT06109935

Intervention type: DRUG
Intervention: Somapacitan
Description: Sogroya® treatment regimen will be in accordance with the approved product labelling in Japan.
Study: NCT06266546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Prophylactic tranexamic acid will be instilled via endobronchial route in all patients undergoing transbronchial cryobiopsy. The medication will be administered through the bronchoscope one minute prior to the cryobiopsy. 500 mg of TXA diluted in 10 ml of saline and the procedure would be carried out as usual.
Study: NCT05970328

Intervention type: DEVICE
Intervention: Hexoskin Medical System
Description: Participant wears both the Hexoskin Medical System and the Nasiff Holter Monitor at the same time to acquire ECG recordings.
Study: NCT05554679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is an oral insulin-sensitising medication that acts to decrease blood glucose concentrations. It inhibits pathways in the liver that stimulate glucose production and also acts to increase glucose uptake into skeletal muscle and fat cells . Metformin is commonly used in the treatment of type 2 diabetes mellitus and polycystic ovarian syndrome , and is being used increasingly in the treatment of gestational diabetes, having been shown to result in decreased rates of neonatal hypoglycaemia and no increased risk of adverse maternal outcomes when compared with insulin.
Study: NCT06274957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONTROL
Description: Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEP DEVICE
Description: Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education~PEP training was applied using the Acapella device.~In addition, participants were subjected to two sessions of 10 minutes each with the Acapella device. In the study, the Acapella device, capable of sustaining expiratory flow of at least 15 L/min for 3 seconds, was activated by taking a deep breath, holding the breath for 2-3 seconds, and then exhaling into the device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFCWO DEVICE
Description: Patients were provided with conventional exercises including Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education~In addition, participants will receive High-Frequency Chest Wall Oscillation (HFCWO) therapy twice a day for 10 minutes each.~HFCWO training was applıed using the WEST device
Study: NCT05391555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil Hydrochloride
Description: Infusion of 0.2 µg/k/m for 5 minutes, the 0.3 µg/k/m for 5 minutes. Pupillary measurements will be taken at baseline and every 2.5 minutes during the 10-minute infusion and 25-minute recovery period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil Hydrochloride
Description: Infusion of 0.2 µg/k/m for 5 minutes, the 0.3 µg/k/m for 5 minutes. Pupillary measurements will be taken at baseline and every 2.5 minutes during the 10-minute infusion and 25-minute recovery period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupillometry measurement
Description: The pupil will be examined with the pupillometer at regular intervals, before during and after the opioid infusion
Study: NCT06476886

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Crisis Intervention (ICI)
Description: The Pilot Phase will consist of 20 youth admitted to YCSU and their parents receiving ICI.~In the randomized control trial (RCT), 60 youth will be randomized in a 1:1 ratio to YCSU (n=30) or APIU (n=30).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adolescent Psychiatric Inpatient Unit (APIU)
Description: In the randomized control trial (RCT), 60 youth will be randomized in a 1:1 ratio to YCSU (n=30) or APIU (n=30).